Study title:
A Phase 1, Multicenter, Single-arm, Dose--escalation Study of CC 97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Relapsing Forms of Multiple Sclerosis (RMS) or Progre
Long title:
A Phase 1, Multicenter, Single-arm, Dose--escalation Study of CC 97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Relapsing Forms of Multiple Sclerosis (RMS) or Progressive Forms of Multiple Sclerosis (PMS) (CA061-1006)
Date receipt dossier:
1 Mar 2024
EudraCT number:
2023-507820-22
Pharmaceutical study code:
CC-97540 (BMS-986353)
Company / Sponsor:
Celgene
Phase:
I
Treated organism:
Humans
Indication category:
Immune disease
Disease:
Relapsing Forms of Multiple Sclerosis (RMS) or Progressive Forms of Multiple Sclerosis (PMS)
Therapeutic approach:
Immunotherapy
Genetic modification:
CD19 CAR
Method of transfer of nucleic acid of interest:
Lentiviral vector
Route of administration:
Intravenous
Locations in Belgium:
UZ Gent
Type of procedure:
Contained use only
Current status:
Authorized